AI Engines For more Details: Perplexity Kagi Labs You
Antiparasitic Action: Albendazole is a broad-spectrum anthelmintic agent that works by interfering with the microtubule function in the cells of parasites. This leads to disruption of their metabolism, inhibition of glucose uptake, and eventual death of the parasites.
Treatment of Intestinal Worm Infections: Albendazole is used in the treatment of various intestinal worm infections, including:
Treatment of Tissue Worm Infections: Albendazole is also used in the treatment of certain tissue worm infections, including:
Dosage and Administration: Albendazole is usually administered orally in the form of tablets or suspension. The dosage and duration of treatment depend on the type and severity of the infection. It is often taken with food to enhance absorption and reduce the risk of gastrointestinal side effects.
Efficacy: Albendazole is highly effective against a wide range of parasitic worms, leading to clearance of the infection and resolution of symptoms in most cases. However, treatment failure or recurrence of infection may occur in some individuals, particularly in areas where reinfection is common or in cases of drug resistance.
Side Effects: Common side effects of albendazole may include gastrointestinal symptoms such as abdominal pain, nausea, vomiting, diarrhea, or constipation. These side effects are usually mild and transient and may resolve with continued use. Allergic reactions such as rash or itching may occur rarely.
Liver Function Monitoring: Albendazole may rarely cause hepatotoxicity (liver damage), particularly at higher doses or with prolonged use. Patients should undergo regular monitoring of liver function tests (e.g., alanine transaminase, aspartate transaminase) during treatment, especially in individuals with pre-existing liver disease.
Contraindications: Albendazole is contraindicated in individuals with known hypersensitivity to the drug or its components. It should be used with caution in pregnant women, as animal studies have shown potential embryotoxic and teratogenic effects. The potential benefits of treatment should be weighed against the risks in pregnant patients.
Drug Interactions: Albendazole may interact with certain medications, including cimetidine, dexamethasone, and praziquantel. Concurrent use should be monitored, and dosage adjustments may be necessary to avoid potential interactions or adverse effects.
Preventive Measures: In addition to treatment with albendazole, preventive measures such as improved sanitation, hygiene practices, and deworming programs may be implemented to reduce the risk of parasitic infections, particularly in endemic areas.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.7 | 0.7 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | |
| Allergies | 1.5 | 0.5 | 2 |
| Allergy to milk products | 0.7 | 0.2 | 2.5 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 1 | 2.1 | -1.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.8 | -1 |
| Ankylosing spondylitis | 1.7 | 0.2 | 7.5 |
| Anorexia Nervosa | 1.2 | -1.2 | |
| Antiphospholipid syndrome (APS) | 1.9 | 1.9 | |
| Asthma | 0.6 | -0.6 | |
| Atherosclerosis | 0.2 | 1.4 | -6 |
| Atrial fibrillation | 1.2 | 0.2 | 5 |
| Autism | 2.6 | 2.1 | 0.24 |
| Barrett esophagus cancer | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 0.4 | 0.7 | -0.75 |
| Brain Trauma | 0.5 | -0.5 | |
| Carcinoma | 1.4 | 0.7 | 1 |
| Celiac Disease | 1 | 0.8 | 0.25 |
| Cerebral Palsy | 0.6 | 1.1 | -0.83 |
| Chronic Fatigue Syndrome | 0.8 | 1.6 | -1 |
| Chronic Kidney Disease | 1.2 | 0.5 | 1.4 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 0.5 | 2 |
| Chronic Urticaria (Hives) | 1.2 | 0.1 | 11 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 1.6 | -0.33 |
| Colorectal Cancer | 2.3 | 2.3 | |
| Constipation | 0.2 | 0.9 | -3.5 |
| Coronary artery disease | 0.2 | 0.5 | -1.5 |
| COVID-19 | 3 | 5.2 | -0.73 |
| Crohn's Disease | 1.9 | 1.2 | 0.58 |
| cystic fibrosis | 0.7 | 0.5 | 0.4 |
| deep vein thrombosis | 0.7 | 1.1 | -0.57 |
| Depression | 2.1 | 2 | 0.05 |
| Dermatomyositis | 0.5 | 0.5 | |
| Eczema | 0.2 | 1.5 | -6.5 |
| Endometriosis | 1.7 | 0.2 | 7.5 |
| Epilepsy | 1.3 | 0.6 | 1.17 |
| Fibromyalgia | 1 | 1 | |
| Functional constipation / chronic idiopathic constipation | 1.8 | 1.5 | 0.2 |
| gallstone disease (gsd) | 0.9 | 0.5 | 0.8 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | -1.5 | |
| Generalized anxiety disorder | 1.2 | 1.2 | |
| Glioblastoma | 0.5 | -0.5 | |
| Graves' disease | 1 | -1 | |
| Halitosis | 0.5 | -0.5 | |
| Hashimoto's thyroiditis | 2 | 2 | |
| Hidradenitis Suppurativa | 0.5 | 0.5 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.9 | 1 | -0.11 |
| hypercholesterolemia (High Cholesterol) | 0.1 | -0.1 | |
| hyperglycemia | 0.2 | 0.6 | -2 |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypersomnia | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 1 | 1.5 | -0.5 |
| Hypothyroidism | 0.5 | -0.5 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0 | 0 | |
| Inflammatory Bowel Disease | 2.2 | 2.6 | -0.18 |
| Insomnia | 1 | 0.5 | 1 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 1.4 | 0.6 | 1.33 |
| Liver Cirrhosis | 1.9 | 1.2 | 0.58 |
| Long COVID | 1.3 | 2.6 | -1 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.2 | 0.8 | -3 |
| ME/CFS with IBS | 0.5 | 1 | -1 |
| ME/CFS without IBS | 0.6 | 0.1 | 5 |
| Metabolic Syndrome | 2.4 | 1.8 | 0.33 |
| Mood Disorders | 2.4 | 2 | 0.2 |
| multiple chemical sensitivity [MCS] | 1.5 | 0.5 | 2 |
| Multiple Sclerosis | 2.4 | 1.2 | 1 |
| Multiple system atrophy (MSA) | 0.2 | 0.7 | -2.5 |
| Neuropathy (all types) | 1 | 0.2 | 4 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 1.8 | -0.5 |
| Obesity | 3 | 1.9 | 0.58 |
| obsessive-compulsive disorder | 2.6 | 1.6 | 0.63 |
| Osteoarthritis | 0.7 | 0.2 | 2.5 |
| Osteoporosis | 0.4 | 0.6 | -0.5 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 1.1 | 2.8 | -1.55 |
| Polycystic ovary syndrome | 0.9 | 0.9 | 0 |
| Premenstrual dysphoric disorder | 0.5 | 0.5 | |
| primary biliary cholangitis | 0 | 0 | |
| Psoriasis | 1.7 | 0.6 | 1.83 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 0.5 | 3 |
| Rosacea | 1.2 | 0.5 | 1.4 |
| Schizophrenia | 0.3 | 1.1 | -2.67 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 1.2 | 0.5 | 1.4 |
| Sleep Apnea | 0.7 | 0.9 | -0.29 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 1 | |
| Stress / posttraumatic stress disorder | 1 | 0.6 | 0.67 |
| Systemic Lupus Erythematosus | 1.2 | 1.2 | 0 |
| Tic Disorder | 0.2 | 0.1 | 1 |
| Tourette syndrome | 0.1 | 0.1 | |
| Type 1 Diabetes | 0.9 | 1 | -0.11 |
| Type 2 Diabetes | 2.4 | 2.3 | 0.04 |
| Ulcerative colitis | 1.7 | 0.6 | 1.83 |
| Unhealthy Ageing | 1.5 | 0.5 | 2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.